ArticleEuropean heart journal open2024
Performance of CHA
Article in European heart journal open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Predictive Performance of HAS-BLED Score in Patients with Atrial Fibrillation and Cancer: A Meta-Analysis.Cardiology · 2026Pooled it
- Component-level associations of anemia and renal dysfunction with competing first events in acute heart failure with atrial fibrillation.Heart and vessels · 2026Article
- Digital Rhythm Surveillance After Postoperative Atrial Fibrillation in Cancer Survivors: A Cardio-Oncology Survivorship Pathway.Medicina (Kaunas, Lithuania) · 2026Review
- Atrial fibrillation and ischemic stroke in cancer: the latest scientific evidence, current management, and future directions.Journal of thrombosis and thrombolysis · 2025Review
- The B-SCancers · 2025Article
- Advance at a glance: contributions to cardio-oncology.European heart journal open · 2025Article
- Controversies in Antithrombotic Therapy for Patients With Coronary Artery Disease and Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Literature Review.Clinical Medicine Insights. Cardiology · 2025Review
- Research progress on bleeding risk assessment models in anticoagulant therapy.Frontiers in cardiovascular medicine · 2025Review
- Left Atrial Appendage Occlusion in Cancer-Associated Atrial Fibrillation: Who, When, and How to Manage Antithrombotic Therapy.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisReview
- Cancer, Inflammation, and Thrombosis: Drivers of Atrial Fibrillation in Oncology Patients.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: To compare the predictive performance of CHA Methods and results: Using data from the Clinical Practice Research Datalink in England, we performed a retrospective cohort study of patients with new diagnoses of AF from 2009 to 2019. Cancer was defined as history of breast, prostate, colorectal, lung, or haematological cancer. We calculated the CHA Conclusion: Amongst certain cancer cohorts in the AF population, CHA
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.